Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAMETA
NL-OMON60868Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in papillary renal cell carcinoma (PRCC) comparing Savolitinib + durvalumab, Sunitinib and Durvalumab monotherapy (3 arms). Primary endpoint: Progression-free survival. Started Dec 2021; status: active, not recruiting.
02
Drugs
savolitinibdurvalumabsunitinib
03
Conditions
papillary renal cell carcinoma (PRCC)
Beyond the preview
Go deeper on NL-OMON60868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60868.